In adrenocortical cancer, GPER1 presented tumor suppressive properties as GPER1 agonists suppressed adrenocortical carcinoma proliferation via cell cycle arrest, DNA damage, and apoptosis via ERK1/2 activation [18]. Here, MAPK3 is linked to neoplasm.